Health Trials

A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

ConditionJuvenile Idiopathic Arthritis
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age1-18
SponsorEli Lilly and Company

About this trial

The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.

Eligibility criteria

Qualifiers

Participants must have completed a previous study of baricitinib for the treatment of JIA.

Disqualifiers

Participants must not have had a permanent discontinuation of baricitinib in the prior study.

Participants must have not developed an allergy to baricitinib.

Trial design

Treatments tested in this trial

  • Baricitinib

Treatment groups

190 Participants
are divided into 1 treatment group

Sponsors and collaborators

Eli Lilly and Company

Lead sponsor

Source ClinicalTrials.gov